Gene‑Edited Pig Kidney Buys 271 Days of Dialysis‑Free Life Before a Human Transplant

Tim Andrews, a 66‑year‑old from New Hampshire, knows all too well how exhausting dialysis can be. When his doctors offered a radically different option – a kidney from a gene‑edited miniature pig – he was understandably skeptical, but also desperate for a break from the endless cycles of treatment.

What happened next reads like science‑fiction, yet it is very much real. The pig, a Yucatan miniature breed, was engineered with 69 precise genetic edits. These edits were designed to strip away the proteins that usually trigger human immune rejection and to block any chance of pig viruses slipping into the recipient.

On the day of the operation, surgeons at Mass General Brigham placed the organ into Andrews’ abdomen. Within minutes the kidney started filtering blood – a clear sign that the xenotransplant was functioning. For the next nine months, Andrews went about his daily routine – cooking, walking his dog, even taking up light gardening – all without a single dialysis session. “I felt alive again,” he later recalled, his voice a mix of relief and disbelief.

Of course, no miracle lasts forever. Around the six‑month mark, subtle changes began to show up in the organ’s tiny blood vessels, and inflammation started to creep in. By day 271, the pig kidney’s performance had waned enough that surgeons decided to remove it. Crucially, extensive blood tests showed that Andrews’ immune system had not been sensitised by the animal organ; no antibodies that could jeopardise a future human transplant were detected, and no porcine endogenous retroviruses were found.

After a brief return to dialysis – just long enough to keep him stable – a human kidney from a deceased donor arrived. The transplant went smoothly, and the new organ is now functioning as expected. In other words, the pig kidney served its purpose: a temporary bridge that bought Andrews precious time while a suitable human donor was located.

This case is more than a personal triumph; it’s a proof‑of‑concept that xenotransplantation can be a viable stop‑gap in the chronic organ shortage crisis that haunts health systems worldwide. Researchers caution that many questions remain – especially around long‑term immunosuppression and scaling the technology – but the 271‑day milestone provides a concrete data point for future trials.

For the millions stuck on endless dialysis waiting lists, the news offers a sliver of hope. If scientists can refine the editing process and prove safety at larger scales, genetically modified animal organs could become a routine bridge, easing the pressure on scarce human donors and, perhaps one day, even supplementing them.